Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Agios Pharmaceuticals (AGIO) Operating Margin (2016 - 2025)

Historic Operating Margin for Agios Pharmaceuticals (AGIO) over the last 13 years, with Q3 2025 value amounting to 907.37%.

  • Agios Pharmaceuticals' Operating Margin rose 2395600.0% to 907.37% in Q3 2025 from the same period last year, while for Sep 2025 it was 1061.8%, marking a year-over-year increase of 1763000.0%. This contributed to the annual value of 1166.47% for FY2024, which is 2930500.0% up from last year.
  • Agios Pharmaceuticals' Operating Margin amounted to 907.37% in Q3 2025, which was up 2395600.0% from 1020.12% recorded in Q2 2025.
  • Agios Pharmaceuticals' 5-year Operating Margin high stood at 907.37% for Q3 2025, and its period low was 12156.85% during Q1 2022.
  • For the 4-year period, Agios Pharmaceuticals' Operating Margin averaged around 2165.56%, with its median value being 1363.66% (2023).
  • Per our database at Business Quant, Agios Pharmaceuticals' Operating Margin soared by 105413600bps in 2023 and then crashed by -976300bps in 2025.
  • Over the past 4 years, Agios Pharmaceuticals' Operating Margin (Quarter) stood at 2300.97% in 2022, then soared by 35bps to 1496.23% in 2023, then rose by 22bps to 1165.3% in 2024, then rose by 22bps to 907.37% in 2025.
  • Its Operating Margin stands at 907.37% for Q3 2025, versus 1020.12% for Q2 2025 and 1221.97% for Q1 2025.